Financial Performance - The unaudited condensed consolidated results for the six months ended June 30, 2024, show a significant increase in revenue compared to the same period in 2023[8]. - The Group reported a profit of HKD 150 million, representing a 20% increase year-on-year[8]. - Revenue for the six months ended June 30, 2024, was HK3,894.9million,representinga10.93,512.9 million in the same period of 2023[9]. - Total income for the period was HK3,972.5million,withcostofsalesandotherdirectcostsamountingtoHK1,459.0 million, resulting in a gross profit of HK2,513.5million[9].−ThecompanyreportedalossfortheperiodofHK108.2 million, compared to a loss of HK25.8millioninthesameperiodof2023,indicatingasignificantdeclineinprofitability[11].−BasicanddilutedlosspersharefortheperiodwasHK0.06, compared to HK0.05inthepreviousyear[9].−ThecompanyreportedatotalcomprehensiveexpenseofHK137.2 million for the period, compared to HK1,155.5millioninthesameperiodof2023,indicatingasignificantreductioninoveralllosses[11].−ThecompanyreportedaprofitbeforetaxationofHK55.1 million for the period, compared to a loss of HK108.2millioninthepreviousyear[63].−ProfitbeforetaxationforthesixmonthsendedJune30,2024,wasHK 105.3 million, compared to HK67.9millionin2023,representingasignificantincrease[82].RevenueSegments−RevenuefromcontractswithcustomersforthesixmonthsendedJune30,2024,wasHK1,531.6 million, a 44% increase from HK1,063.7millionin2023[60].−ThehealthcareservicessegmentgeneratedrevenueofHK800.4 million, up from HK170.9millionin2023,markingasignificantincreaseof36898.7 million, compared to HK54.7millionintheprioryear,indicatinganincreaseofapproximately80.51,567.7 million, showing a slight decrease from HK1,628.6millioninthepreviousyear[63].−SalesofcompletedpropertiesdecreasedtoHK319.1 million in 2024 from HK750.3millionin2023,representingadeclineof57.5 83,470.4 million, a decrease from HK86,031.6millionasofDecember31,2023,reflectingadeclineofapproximately3.6 15,031.9 million from HK14,240.1million,representingagrowthofabout5.6 43,322.7 million from HK43,538.9million,adeclineofapproximately0.5 29,467.9 million, up from HK27,778.0million,indicatinganincreaseofabout6.1 12,665.9 million from HK14,702.0million,adeclineofabout13.9956.4 million, an increase from HK845.0millioninthepreviousyear,indicatinghigherinvestmentinmarketpresence[9].−Researchanddevelopmentexpenseshaveincreasedby30 604.0 million for 2024, up from HK673.5millionin2023,indicatingadecreaseofapproximately10.3 656.1 million, up from HK612.2millioninthepreviousyear,markinganincreaseofapproximately7.2 412.9 million in dividends recognized in 2023[93]. Financial Assets and Liabilities - The total fair value of financial assets measured at fair value was HK14,921.3millionasof30thJune2024[109].−TheGroup′sfinancialassetsatfairvaluethroughprofitorloss(FVTPL)includedLevel2debtsecuritiesandlistedperpetualsecurities,withfairvaluesderivedfromquotedpricesfrompricingservices[123].−TheimpairmentallowanceforloansandadvancestoconsumerfinancecustomerswasHK 10,920.4 million, slightly reduced from HK11,197.0millioninthepreviousperiod[195].−ThenetunrealizedlossonLevel3financialassetsatfairvaluethroughprofitorlosswasHK 54.4 million as of June 30, 2024, compared to HK$ 5.6 million in 2023[192]. Accounting Policies and Changes - The Group changed its accounting policy for measuring hospital and other buildings in the PRC from a revaluation model to a cost model, which is expected to provide more reliable information reflecting operational performance[54]. - The application of amendments to HKFRSs in the current interim period has had no material impact on the Group's financial positions and performance[52]. - The Group's accounting policy change does not impact profit or loss or loss per share for the six months ended June 30, 2024[53].